Get notified when SMMT files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsSummit announces Phase II and Phase III ivonescimab trial results in colorectal cancer
Filed June 1, 2026 · Period ending May 30, 2026 · ~1 min read
Key Changes
-
high
Summit disclosed new Phase II results from AK112-206, a global multicenter trial studying ivonescimab in first-line metastatic colorectal cancer, co-sponsored with partner Akeso.
Item 7.01 view on EDGAR → -
high
Partner Akeso published Phase III results from HARMONi-6, a China-based study of ivonescimab. This represents more advanced clinical evidence than Phase II data and was exclusively conducted by Akeso.
Item 7.01 view on EDGAR → -
medium
Summit scheduled a conference call for June 1, 2026 at 7:00am ET to discuss both trial datasets, with presentation slides attached to the filing.
Item 9.01 verify on EDGAR →
This preview is just the start — the full report includes the narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (FNGR 10-Q) is open in full — no account needed.
Partner
Trade SMMT commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · Jun 2, 2026 · How we verify